D-FORTE 50,000 IU Price in UAE

Overview

Welcome to Dwaey, specifically on D-FORTE 50,000 IU page.
This medicine contains an important and useful components, as it consists of
Vitamin D (as Ergocalciferol)is available in the market in concentration

Name

Vitamin D (as Ergocalciferol)

Precaution

Use Ergocalciferol with caution in patients with renal impairment, cardiovascular disease, or a history of kidney stones. Monitor serum calcium, phosphate, and renal function during prolonged therapy. Avoid concurrent use with high doses of calcium or other vitamin D analogs unless prescribed. Patients with sarcoidosis or other granulomatous diseases may have increased sensitivity to vitamin D.

Indication

Ergocalciferol (Vitamin D2) is indicated for the prevention and treatment of vitamin D deficiency, hypoparathyroidism, rickets, and osteomalacia. It is also used as adjunct therapy in managing hypocalcemia in chronic renal dialysis and in conditions associated with malabsorption of vitamin D such as cystic fibrosis and Crohn's disease.

Contra indication

Contraindicated in patients with hypercalcemia, hypervitaminosis D, or known hypersensitivity to ergocalciferol or any of its components. It should also not be used in patients with severe renal impairment unless under specialist supervision due to the risk of hyperphosphatemia and ectopic calcification.

Side Effect

Common side effects include gastrointestinal disturbances such as nausea, vomiting, and constipation. Hypercalcemia may manifest with weakness, headache, dry mouth, metallic taste, polyuria, or nephrocalcinosis. Long-term use at high doses may lead to toxicity characterized by bone demineralization and soft tissue calcification.

Pregnancy Category ID

Information not available

Mode of Action

Ergocalciferol is a provitamin D2 that undergoes hydroxylation in the liver and kidneys to form the active metabolite 1,25-dihydroxyergocalciferol (calcitriol). Calcitriol acts on the intestines to increase calcium and phosphate absorption, promotes bone mineralization, and modulates parathyroid hormone secretion to regulate calcium homeostasis.

Interaction

Concurrent use with thiazide diuretics increases the risk of hypercalcemia. Absorption may be reduced by bile acid sequestrants (e.g., cholestyramine), mineral oil, or orlistat. Digitalis toxicity risk increases with hypercalcemia. Barbiturates and phenytoin may reduce ergocalciferol activity by increasing its metabolism.

Pregnancy Category Note

Category C (FDA). Ergocalciferol should be used during pregnancy only if clearly needed and prescribed by a healthcare provider. Excessive doses may be teratogenic. Normal supplementation under medical supervision is considered safe.

Adult Dose

For vitamin D deficiency: 50,000 IU orally once weekly for 6–8 weeks, followed by maintenance dosing (e.g., 1,000–2,000 IU/day). For hypoparathyroidism: 50,000–200,000 IU daily may be required, adjusted based on serum calcium and phosphate levels.

Child Dose

For deficiency: 8,000–10,000 IU daily for infants and children under 12, typically for 2–3 months. For rickets: 12,000–500,000 IU orally once daily or weekly, based on severity and age, followed by maintenance dosing. Close monitoring is essential in pediatric populations.

Renal Dose

In patients with chronic kidney disease, dosing should be individualized. Lower doses are preferred due to reduced renal conversion to active forms and risk of hyperphosphatemia. Activated vitamin D analogs (e.g., calcitriol) are often preferred in advanced renal failure.

Administration

Administer orally with or without food, preferably with meals to enhance absorption. Available in capsules, softgels, and liquid formulations. In deficiency states, high-dose regimens may require intermittent administration under close supervision with periodic monitoring of calcium, phosphate, and vitamin D levels.